Once again about cardiovascular risk prevention, statins, its adverse effects and benefits

Authors: Golukhova E.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Editorial article


DOI: https://doi.org/10.24022/1997-3187-2021-15-3-303-306

For citation: Golukhova E.Z. Once again about cardiovascular risk prevention, statins, its adverse effects and benefits. Creative Cardiology. 2021; 15 (3): 303–6 (in Russ.). DOI: 10.24022/1997-3187-2021-15-3-303-306

Received / Accepted:  03.09.2021 / 06.09.2021

Keywords: prevention cardiovascular disease statins cardiovascular risk factors

Full text:  

 

Abstract

The associations between statins and adverse events in primary prevention of cardiovascular disease and type and dosage of statins are still less evident comparing with secondary prevention. The author analyzed the results of recent systematic reviews and meta-analysis and real clinical practice data. Primary outcomes were common adverse events: self-reported muscle symptoms, clinically confirmed muscle disorders, liver dysfunction, renal insufficiency, diabetes, and eye conditions. Secondary outcomes included myocardial infarction, stroke, and death from cardiovascular disease as measures of efficacy. For primary prevention of cardiovascular disease, the risk of adverse events attributable to statins was low and did not outweigh their efficacy in preventing cardiovascular disease, suggesting that the benefit-to-harm balance of statins is generally favorable.

References

  1. Cai T., Abel L., Langford O., Monaghan G., Aronson J.K., Stevens R.J. et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021; 374: n1537. DOI: 10.1136/bmj.n1537
  2. Saeed A., Zhu J., Thoma F., Marroquin O., Aiyer A., Agarwala A. et al. Cardiovascular disease risk-based statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network. Circ. Cardiovasc. Qual. Outcomes. 2021. DOI: 10.1161/CIRCOUTCOMES.120.007485

About Authors

Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of RAS, Director; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery